SGLT2 inhibitors decrease the risk for kidney composite outcomes in CVOTs, with similar benefits reported in dedicated kidney outcome trials such as CREDENCE and DAPA‐CKD. The gene discussed is SLC5A2; the disease is chronic kidney disease.